These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 36925714)

  • 21. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
    Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
    Front Public Health; 2022; 10():975781. PubMed ID: 36238255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging vaccine nanotechnology: From defense against infection to sniping cancer.
    Feng C; Li Y; Ferdows BE; Patel DN; Ouyang J; Tang Z; Kong N; Chen E; Tao W
    Acta Pharm Sin B; 2022 May; 12(5):2206-2223. PubMed ID: 35013704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines.
    Namiot ED; Sokolov AV; Chubarev VN; Tarasov VV; Schiöth HB
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.
    Chung YH; Beiss V; Fiering SN; Steinmetz NF
    ACS Nano; 2020 Oct; 14(10):12522-12537. PubMed ID: 33034449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of current COVID-19 vaccine platforms.
    Nagy A; Alhatlani B
    Comput Struct Biotechnol J; 2021; 19():2508-2517. PubMed ID: 33936564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Obesity on Vaccination to SARS-CoV-2.
    Nasr MC; Geerling E; Pinto AK
    Front Endocrinol (Lausanne); 2022; 13():898810. PubMed ID: 35795152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges.
    Singh R; Behera M; Kumari N; Kumar S; Rajput VD; Minkina TM; Adnan M; Siddiqui AJ; Kumar N
    Curr Pharm Des; 2021; 27(41):4197-4211. PubMed ID: 34459371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.
    Tenchov R; Bird R; Curtze AE; Zhou Q
    ACS Nano; 2021 Nov; 15(11):16982-17015. PubMed ID: 34181394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
    Powell J; Piszczatoski CR
    Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19.
    Rahman MM; Ahmed M; Islam MT; Khan MR; Sultana S; Maeesa SK; Hasan S; Hossain MA; Ferdous KS; Mathew B; Rauf A; Uddin MS
    Curr Pharm Des; 2022; 28(12):948-968. PubMed ID: 34218774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.
    Wang D; Yuan Y; Liu B; Epstein ND; Yang Y
    Int J Biol Macromol; 2023 May; 236():123979. PubMed ID: 36907305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.
    Park E; Choi SY; Kim J; Hildebrandt N; Lee JS; Nam JM
    Small Methods; 2023 Jul; 7(7):e2300034. PubMed ID: 37189215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convergence of Nanotechnology and Bacteriotherapy for Biomedical Applications.
    Liu J; Yuan S; Bremmer A; Hu Q
    Adv Sci (Weinh); 2024 Apr; 11(16):e2309295. PubMed ID: 38358998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines.
    Wu Y; Yu S; de Lázaro I
    Nanoscale; 2024 Apr; 16(14):6820-6836. PubMed ID: 38502114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
    Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
    J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smart nano-micro platforms for ophthalmological applications: The state-of-the-art and future perspectives.
    Lyu Q; Peng L; Hong X; Fan T; Li J; Cui Y; Zhang H; Zhao J
    Biomaterials; 2021 Mar; 270():120682. PubMed ID: 33529961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
    Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
    JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis.
    Zhang X; Guo M; Huang Z; Huang Y; Wu C; Pan X
    Infect Med (Beijing); 2022 Jun; 1(2):103-112. PubMed ID: 38013718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle approaches against SARS-CoV-2 infection.
    Duan Y; Wang S; Zhang Q; Gao W; Zhang L
    Curr Opin Solid State Mater Sci; 2021 Dec; 25(6):100964. PubMed ID: 34729031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.